TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
NorthX Biologics AB
Closing information (x1000 SEK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
109,499
|
158,938
|
138,549 |
| Financial expenses |
211
|
789
|
432 |
| Earnings before taxes |
-73,755
|
-11,743
|
-31,837 |
| EBITDA |
-62,600
|
-4,336
|
-22,440 |
| Total assets |
359,201
|
276,411
|
221,448 |
| Current assets |
166,321
|
138,035
|
104,445 |
| Current liabilities |
312,769
|
268,511
|
219,305 |
| Equity capital |
46,432
|
7,900
|
2,143 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
145
|
129
|
124 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
12.9%
|
2.9%
|
1.0% |
| Turnover per employee |
755
|
1,232
|
1,117 |
| Profit as a percentage of turnover |
-67.4%
|
-7.4%
|
-23.0% |
| Return on assets (ROA) |
-20.5%
|
-4.0%
|
-14.2% |
| Current ratio |
53.2%
|
51.4%
|
47.6% |
| Return on equity (ROE) |
-158.8%
|
-148.6%
|
-1485.6% |
| Change turnover |
-49,439
|
20,389
|
48,985 |
| Change turnover % |
-31%
|
15%
|
55% |
| Chg. No. of employees |
16
|
5
|
20 |
| Chg. No. of employees % |
12%
|
4%
|
19% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.